Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma
Document Type
Journal Article
Publication Date
2-1-2021
Journal
Future Oncology
Volume
17
Issue
6
DOI
10.2217/fon-2020-0902
Keywords
dose reduction; dose-response relationship; duration of treatment; electronic health records; liposomal irinotecan; pancreatic ductal adenocarcinoma; retrospective studies; treatment outcome
Abstract
© 2021 Future Medicine Ltd.. All rights reserved. Aim: This study sought to understand the association between liposomal irinotecan dose reductions (DRs) and clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma. Materials & methods: A retrospective study of adult patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan in the Flatiron Health database was conducted to assess treatment and clinical outcomes. Results: DRs occurred in 28.4% of the 320 patients in the study. Patients with DRs had longer overall survival (7.7 [95% CI: 6.2-10.2]) vs 3.6 [3.2-4.1] months) and time to discontinuation (4.2 [3.0-4.9] vs 1.4 [1.0-1.5] months) than patients without DRs. Results were consistent in a validation analysis requiring three cycles of treatment. Conclusion: Liposomal irinotecan DRs were associated with improved clinical outcomes compared with patients without DRs.
APA Citation
Kim, G., Surinach, A., Corvino, F., Cockrum, P., Belanger, B., & Abushahin, L. (2021). Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Future Oncology, 17 (6). http://dx.doi.org/10.2217/fon-2020-0902
